Posted by Michael Wonder on 10 Sep 2020
Terns Pharmaceuticals receives fast track designation for TERN-201 as a treatment for NASH
10 September 2020 - Clinical trial of semicarbazide-sensitive amine oxidase inhibitor TERN-201 in NASH patients planned for early 2021.
Terns Pharmaceuticals today announced that TERN-201, a semicarbazide-sensitive amine oxidase inhibitor, has been granted fast track designation by the U.S. FDA for the treatment of non-alcoholic steatohepatitis.
Terns recently completed a Phase 1 clinical study of TERN-201, which demonstrated that single and multiple oral administrations of TERN-201 were well tolerated with no significant safety findings observed.
